<DOC>
	<DOCNO>NCT01174888</DOCNO>
	<brief_summary>RATIONALE : Bortezomib midostaurin may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , mitoxantrone hydrochloride , etoposide , cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib midostaurin together combination chemotherapy may kill cancer cell . PURPOSE : This phase I trial study side effect best dose bortezomib give together midostaurin without combination chemotherapy treat patient relapsed refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Phase I Combination Midostaurin , Bortezomib , Chemo Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) bortezomib combination midostaurin intensive chemotherapy patient relapsed/refractory acute myeloid leukemia ( AML ) . II . To define specific toxicity dose limit toxicity ( DLT ) midostaurin bortezomib combination intensive chemotherapy relapsed/refractory AML . SECONDARY OBJECTIVES : I . To determine rate complete remission ( CR ) midostaurin bortezomib combination intensive chemotherapy . II . To determine overall response rate ( ORR ) . III . To characterize biological activity midostaurin bortezomib potentially increase endogenous phosphatase activity therefore inhibit aberrant tyrosine kinase assess FLT3 KIT tyrosine kinase activity well SHP-1 ( Anti-Src Homology Phosphatase-1 ) phosphatase activity . IV . To correlate biological activity midostaurin bortezomib potentially increase endogenous phosphatase activity clinical response . V. To conduct pharmacokinetic study midostaurin bortezomib together combination intensive chemotherapy . VI . To determine efficacy midostaurin bortezomib combination intensive chemotherapy maximum tolerate dose patient FLT3 KIT tyrosine kinase mutation . OUTLINE : This dose escalation study bortezomib . Patients assign 1 2 treatment group . GROUP I ( Dose level 1-2 ) : Patients receive oral midostaurin twice daily day 1-14 bortezomib IV day 1 , 4 , 8 , 11 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . GROUP II ( Dose level 3-6 ) : Patients receive mitoxantrone hydrochloride IV 10 minute , etoposide IV 1 hour , cytarabine IV 6 hour day 1-6 . Patients also receive oral midostaurin twice daily day 8-21 bortezomib IV day 8 , 11 , 15 , 18 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Inclusion Criteria Patients age &gt; 18 relapsed refractory acute myeloid leukemia WHO criteria eligible dose level 1 2 . Patients age &gt; 18 ≤ 70 relapsed refractory acute myeloid leukemia WHO criteria eligible dose level 3 6 . Patients secondary AML eligible If patient comorbid medical illness , life expectancy attribute must great 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Patients must adequate organ function define : total bilirubin &lt; 2.0mg/dL ≤1.5 ULN ( institutional upper limit normal ) AST ( aspartate aminotransferase ) ( SGOT ) /ALT ( Alanine aminotransferase ) ( SGPT ) &lt; 2.5 X institutional ULN creatinine &lt; 1.7 mg /dL Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . If patient agree , patient eligible . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients must recover toxicity prior therapy less Grade 2 Patients status post prior hematopoietic stem cell transplantation eligible Exclusion criterion Patients chemotherapy radiotherapy within 2 week ( 6 week nitrosoureas mitomycin C ) prior enter study . Hydroxyurea may administer initiation treatment study Patients receive investigational agent patient receive investigational agent within 14 day enrollment Patients active central nervous system disease granulocytic sarcoma sole site disease Patients history allergic reaction attribute compound similar chemical biologic composition midostaurin , bortezomib , mitoxantrone , etoposide cytarabine easily manage . Patient hypersensitivity bortezomib , boron , mannitol . Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . As infection common feature AML , patient active infection permit enroll provide infection control . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , uncontrolled hypertension , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . Ejection fraction &lt; 50 % Patients serious medical psychiatric illness likely interfere participation clinical study . Pregnant woman woman breastfeed exclude study . Patients preexist Grade 2 high neuropathy serious neurologic toxicity would significantly increase risk complication bortezomib therapy exclude . Patients know confirmed diagnosis HIV infection ( due concern increase toxicity regimen combination HAART ) active viral hepatitis . Patients pulmonary infiltrate include suspect infectious origin . In particular , patient resolution clinical symptom pulmonary infection residual pulmonary infiltrates chest xray eligible pulmonary infiltrates completely resolve . Patients surgical procedure , exclude central venous catheter placement minor procedure ( e.g . skin biopsy ) within 14 day Day 1 . Patients advance malignant solid tumor exclude . Patients know impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption midostaurin . Patients prior midostaurin treatment exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
</DOC>